Temporal activation of WNT/β-catenin signaling is sufficient to inhibit SOX10 expression and block melanoma growth

[1]  Jeffrey Weber,et al.  Long-Term Outcomes in Patients With BRAF V600-Mutant Metastatic Melanoma Who Received Dabrafenib Combined With Trametinib. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  A. Weeraratna,et al.  In the Wnt-er of life: Wnt signalling in melanoma and ageing , 2016, British Journal of Cancer.

[3]  M. Boutros,et al.  Wnt signaling in cancer , 2016, Oncogene.

[4]  A. Salem,et al.  WNT/β-catenin signaling mediates human neural crest induction via a pre-neural border intermediate , 2016, Development.

[5]  A. Hauschild,et al.  Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial. , 2015, The Lancet. Oncology.

[6]  Dirk Schadendorf,et al.  Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. , 2015, The New England journal of medicine.

[7]  J. Larkin,et al.  Pembrolizumab versus Ipilimumab in Advanced Melanoma. , 2015, The New England journal of medicine.

[8]  Steven J. M. Jones,et al.  Genomic Classification of Cutaneous Melanoma , 2015, Cell.

[9]  T. Engler,et al.  Activating the Wnt/β-Catenin Pathway for the Treatment of Melanoma – Application of LY2090314, a Novel Selective Inhibitor of Glycogen Synthase Kinase-3 , 2015, PloS one.

[10]  C. Wellbrock,et al.  Microphthalmia‐associated transcription factor in melanoma development and MAP‐kinase pathway targeted therapy , 2015, Pigment cell & melanoma research.

[11]  S. Ra,et al.  A newly developed mouse monoclonal SOX10 antibody is a highly sensitive and specific marker for malignant melanoma, including spindle cell and desmoplastic melanomas. , 2015, Archives of pathology & laboratory medicine.

[12]  P. Ascierto,et al.  Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. , 2014, The New England journal of medicine.

[13]  Rong Liu,et al.  SOX10 is a novel oncogene in hepatocellular carcinoma through Wnt/β-catenin/TCF4 cascade , 2014, Tumor Biology.

[14]  R. Moon,et al.  WNT5A enhances resistance of melanoma cells to targeted BRAF inhibitors. , 2014, The Journal of clinical investigation.

[15]  R. Moon,et al.  Activation of Wnt/β-Catenin Signaling Increases Apoptosis in Melanoma Cells Treated with Trail , 2013, PloS one.

[16]  W. Shi,et al.  The Subread aligner: fast, accurate and scalable read mapping by seed-and-vote , 2013, Nucleic acids research.

[17]  A. Weeraratna,et al.  A Wnt-er Migration: The Confusing Role of β-Catenin in Melanoma Metastasis , 2013, Science Signaling.

[18]  Dean Y. Li,et al.  The Small GTPase ARF6 Stimulates β-Catenin Transcriptional Activity During WNT5A-Mediated Melanoma Invasion and Metastasis , 2013, Science Signaling.

[19]  A. Hauschild,et al.  Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[20]  M. Okoniewski,et al.  Sox10 promotes the formation and maintenance of giant congenital naevi and melanoma , 2012, Nature Cell Biology.

[21]  Hans Clevers,et al.  Wnt/β-Catenin Signaling and Disease , 2012, Cell.

[22]  R. Moon,et al.  Wnt/β-Catenin Signaling and AXIN1 Regulate Apoptosis Triggered by Inhibition of the Mutant Kinase BRAFV600E in Human Melanoma , 2012, Science Signaling.

[23]  D. Rimm,et al.  β-catenin signaling controls metastasis in Braf-activated Pten-deficient melanomas. , 2011, Cancer cell.

[24]  Axel Hoos,et al.  Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. , 2011, The New England journal of medicine.

[25]  S. Haggarty,et al.  Chemical-genetic screen identifies riluzole as an enhancer of Wnt/β-catenin signaling in melanoma. , 2010, Chemistry & biology.

[26]  Davis J. McCarthy,et al.  edgeR: a Bioconductor package for differential expression analysis of digital gene expression data , 2009, Bioinform..

[27]  Gurpreet W. Tang,et al.  COSMIC (the Catalogue of Somatic Mutations in Cancer): a resource to investigate acquired mutations in human cancer , 2009, Nucleic acids research.

[28]  Xi He,et al.  Wnt/beta-catenin signaling: components, mechanisms, and diseases. , 2009, Developmental cell.

[29]  R. Moon,et al.  Activated Wnt/ß-catenin signaling in melanoma is associated with decreased proliferation in patient tumors and a murine melanoma model , 2009, Proceedings of the National Academy of Sciences.

[30]  L. Chiriboga,et al.  Sox10: A Pan-Schwannian and Melanocytic Marker , 2008, The American journal of surgical pathology.

[31]  Sébastien Lê,et al.  FactoMineR: An R Package for Multivariate Analysis , 2008 .

[32]  E. Steingrímsson,et al.  The Microphthalmia-Associated Transcription Factor Mitf Interacts with β-Catenin To Determine Target Gene Expression , 2006, Molecular and Cellular Biology.

[33]  L. Akslen,et al.  Importance of P-Cadherin, β-Catenin, and Wnt5a/Frizzled for Progression of Melanocytic Tumors and Prognosis in Cutaneous Melanoma , 2005, Clinical Cancer Research.

[34]  A. Trumpp,et al.  Metastasizing melanoma formation caused by expression of activated N-RasQ61K on an INK4a-deficient background. , 2005, Cancer research.

[35]  Juergen Kast,et al.  Identification of protein‐protein interactions using in vivo cross‐linking and mass spectrometry , 2004, Proteomics.

[36]  R. Mayor,et al.  Identification of neural crest competence territory: Role of Wnt signaling , 2004, Developmental dynamics : an official publication of the American Association of Anatomists.

[37]  J. Nesland,et al.  Reduced beta-catenin expression in the cytoplasm of advanced-stage superficial spreading malignant melanoma. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[38]  E. Price,et al.  β-Catenin–induced melanoma growth requires the downstream target Microphthalmia-associated transcription factor , 2002, The Journal of Cell Biology.

[39]  M. Wolter,et al.  Molecular genetic analysis of malignant melanomas for aberrations of the WNT signaling pathway genes CTNNB1, APC, ICAT and BTRC , 2002, International journal of cancer.

[40]  C. Marcelle,et al.  Ectodermal Wnt Function as a Neural Crest Inducer , 2002, Science.

[41]  M. Wegner,et al.  Sox10 Is an Active Nucleocytoplasmic Shuttle Protein, and Shuttling Is Crucial for Sox10-Mediated Transactivation , 2002, Molecular and Cellular Biology.

[42]  C. Wolf‐peeters,et al.  Loss of Membranous Expression of β-Catenin Is Associated with Tumor Progression in Cutaneous Melanoma and Rarely Caused by Exon 3 Mutations , 2002, Modern Pathology.

[43]  T. Saida,et al.  Loss of β‐catenin expression associated with disease progression in malignant melanoma , 2001, The British journal of dermatology.

[44]  J. Hansson,et al.  Cytoplasmic and nuclear accumulation of β‐catenin is rarely caused by CTNNB1 exon 3 mutations in cutaneous malignant melanoma , 2001, International journal of cancer.

[45]  R. Ballotti,et al.  Direct Regulation of the Microphthalmia Promoter by Sox10 Links Waardenburg-Shah Syndrome (WS4)-associated Hypopigmentation and Deafness to WS2* , 2000, The Journal of Biological Chemistry.

[46]  M. Wegner,et al.  Interaction among SOX10, PAX3 and MITF, three genes altered in Waardenburg syndrome. , 2000, Human molecular genetics.

[47]  W. Pavan,et al.  Transcription factor hierarchy in Waardenburg syndrome: regulation of MITF expression by SOX10 and PAX3 , 2000, Human Genetics.

[48]  D. Raible,et al.  Direct regulation of nacre, a zebrafish MITF homolog required for pigment cell formation, by the Wnt pathway. , 2000, Genes & development.

[49]  Randall T. Moon,et al.  Control of neural crest cell fate by the Wnt signalling pathway , 1998, Nature.

[50]  Paul Polakis,et al.  Stabilization of β-Catenin by Genetic Defects in Melanoma Cell Lines , 1997, Science.

[51]  Joshua M. Stuart,et al.  Integrative Analysis Identifies Four Molecular and Clinical Subsets in Uveal Melanoma. , 2018, Cancer cell.

[52]  Thomas R. Gingeras,et al.  STAR: ultrafast universal RNA-seq aligner , 2013, Bioinform..

[53]  Gurpreet W. Tang,et al.  COSMIC (the Catalogue of Somatic Mutations in Cancer): a resource to investigate acquired mutations in human cancer , 2010, Nucleic Acids Res..

[54]  P. Robbins,et al.  Stabilization of beta-catenin by genetic defects in melanoma cell lines. , 1997, Science.